Chimeric antigen receptor (CAR) T-cell therapy for certain cancers comes with important side effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Use ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance.

Blocking structural changes may restore the effectiveness of the cancer drug venetoclax, according to Rutgers Health researchers and others ...

IDH1 inhibitors show strong efficacy and tolerability in IDH1-mutated AML and MDS, with some patients achieving long-term remissions. Molecular characteristics, such as lower mutational and blast ...

Cellectis SA ( ($CLLS) ) has provided an announcement. On October 16, 2025, Cellectis S.A. hosted an Investors R&D Day, unveiling promising data ...

No, Lil Miquela does not have leukemia. That’s because Miquela — who has a whopping 5 million followers across her Instagram and TikTok accounts — is not a real person.

Discusses Clinical Update on AB8939 Combined With Venetoclax for Refractory and Relapsed AML With Poor Genetics October 16, ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

Treatment Market is entering a decade of strong transformation and clinical advancement. Estimated at USD 679.5 million in 2025, the market is projected to nearly double to USD 1,294.9 million by 2035 ...